Hip Fracture Study of GSK576428 (Fondaparinux Sodium)

Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Hip Fracture Surgery

This study is requested by PMDA to confirm the efficacy and the safety for HFS.

Inclusion Criteria:

• Patients undergoing hip fracture surgery within 10 days following the time of fracture of the hip (proximal femur) (or following the time of fracture estimated from trauma).

Exclusion Criteria:

• Active, clinically significant bleeding (excluding drainage).